In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covidien Expects Continued Growth In Neurovascular Division

Executive Summary

With more than $30 million invested in stroke clinical trials and technology, Covidien sees tremendous opportunity in the endovascular treatment of acute ischemic stroke. The company’s ongoing research is laying the foundation for continued growth in its neurovascular division.

Advertisement

Related Content

Endovascular Devices Headline International Stroke Conference
Stroke Devices: Hope Amid Headwinds

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel